7 completed. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 2 | Completed 2 |
Follow Clavis Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia Elacytarabine plus idarubicin - Acute Myeloid Leukemia | Phase 2 | Completed | Clavis Pharma | 51 | 2009-12-01 | 2013-09-27 |
| A Study of CP-4126 in Patients With Advanced Pancreatic Cancer IV CP-4126 - Advanced Adenocarcinoma of Pancreas | Phase 2 | Completed | Clavis Pharma | 21 | 2009-04-01 | 2012-02-10 |
| A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer CP-4055 - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Clavis Pharma | 28 | 2008-04-01 | 2013-09-13 |
| A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer CP-4055 - Advanced Colorectal Cancer, Colorectal Cancer | Phase 2 | Completed | Clavis Pharma | 16 | 2007-05-01 | 2009-06-04 |
| Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma CP-4055, Sorafenib (Nexavar) - Malignant Melanoma | Phase 2 | Completed | Clavis Pharma | 18 | 2007-03-01 | 2013-09-12 |
| A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies CP-4055 - Hematologic Malignancies, AML | Phase 1 / Phase 2 | Completed | Clavis Pharma | 153 | 2006-05-01 | 2013-09-18 |
| Clinical Study of Previously Untreated Patients With Malignant Melanoma CP-4055 (ELACYT) - Malignant Melanoma, Neoplasm Metastasis | Phase 2 | Completed | Clavis Pharma | 42 | 2005-09-01 | 2007-07-10 |
Neoplasms (5) · Neoplasm Metastasis (3) · Melanoma (2) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Ovarian Neoplasms (1) · Recurrence (1)
5'-oleoyl cytarabine (6) · CP 4126 (1) · Idarubicin (1) · Sorafenib (1)
Norway (5) · United States (4) · Belgium (2) · France (2) · Germany (2) · Italy (2) · Sweden (2) · United Kingdom (2)
David A Rizzieri, MD (1) · Francis J Giles, MD (1) · Jim Cassidy, MBChB, MD (1) · Sandro Pignata, MD (1) · Svein Dueland, MD (1) · Svein Dueland, MD, Ph.D (1)